Jasper Therapeutics, Inc. Announces Reverse Stock Split
January 02, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 11, 2023 16:05 ET
|
Jasper Therapeutics, Inc.
First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug....
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
May 12, 2023 16:05 ET
|
Jasper Therapeutics, Inc.
Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in...
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 10, 2022 16:05 ET
|
Jasper Therapeutics, Inc.
Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia PatientsFast Track Designation...
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 16:05 ET
|
Jasper Therapeutics, Inc.
Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients...
Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update
March 18, 2022 16:05 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies,...
Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that...
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer
February 28, 2022 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the...